|
Mar 12
|
After surprise trial failure, ALS doctors brace for one less treatment option
|
|
Mar 11
|
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
|
|
Mar 11
|
Amylyx CEOs look for a path forward following major setback
|
|
Mar 10
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Analysts Are Reducing Their Forecasts For This Year
|
|
Mar 10
|
Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.
|
|
Mar 8
|
Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure
|
|
Mar 8
|
Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work
|
|
Mar 8
|
Amylyx’s ALS Drug Fails Trial, Raising Questions About Company’s Future
|
|
Mar 8
|
10 Biotech Stocks with Huge Potential
|
|
Mar 8
|
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
|
|
Mar 8
|
Amylyx ALS drug fails crucial study, putting company’s future in doubt
|
|
Jan 5
|
2 Biotech Stocks With Huge Catalysts in 2024
|
|
Dec 26
|
Is Amylyx (AMLX) Stock a Solid Choice Right Now?
|
|
Dec 22
|
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
|
|
Dec 4
|
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
|
|
Nov 29
|
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 28
|
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
|
|
Nov 27
|
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
|
|
Nov 12
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript
|
|
Nov 10
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock's 34% Dive Might Signal An Opportunity But It Requires Some Scrutiny
|